Three quarters of a mile from civilization

Views, analysis & commentary - essentially on venture capital & pharmaceutical industry

Sunday, March 31, 2013

Factors Influencing the Global Prospects & Investor Attractiveness of Indian Pharmaceutical Industry

›
Most ‘Indian Pharma Outlook’ reports from the likes of McKinsey & PwC   almost exclusively focus their policy & regulatory scen...
3 comments:
Thursday, March 21, 2013

You'd never guess what people could do under their loft beds!!

›
Hobbyists By A VC http://www.avc.com/a_vc/2013/03/hobbyists.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AVc...
Sunday, March 17, 2013

IT & ITeS Enterprise in India: an Outsider Perspective based on trends in Investment & Technological Evolution

›
Why should an outsider perspective matter? I tend to believe that way too many people have taken Steve Jobs maxim, ‘ customers cannot tel...
2 comments:
Sunday, March 10, 2013

Modi's WIEF woes & Why I'm pissed!

›
Not sure who’s pissing me off more… The holier-than-the-pope trio of desi professors that merrily went about occupying Philly then ...
Wednesday, March 6, 2013

Will Mylan's acquisition of Agila benefit Accel Partners?

›
Okay, the story goes like this.... Way back in 2007, Accel partners committed to invest & invested over the next three years 1....
1 comment:
Tuesday, March 5, 2013

What could VCs learn from the recent pharma deals involving biotechs with very early-assets?

›
My response on the blog post " Preclinical Biotech Structured Deals: Reflections on 2013′s Solid Start"   by Bruce Booth - post...
Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
‹
›
Home
View web version
Powered by Blogger.